Johnson & Johnson licenses Vedanta’s bowel disease drug

SHARE Johnson & Johnson licenses Vedanta’s bowel disease drug

BOSTON — Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body.

J&J’s Janssen Pharmaceutical Cos. unit says Vedanta Biosciences of Boston could receive up to $241 million, including an upfront payment and additional ones if a medicine gets approved for a bowel disease such as ulcerative colitis or Crohn’s disease.

The experimental treatment, called VE202, hasn’t been studied in people but has shown effectiveness in animal tests. J&J will handle future testing.

The two companies could expand the partnership to treatments for additional conditions.

Johnson & Johnson, based in New Brunswick, New Jersey, is a leader in treatments for inflammatory bowel and other immune disorders, selling Remicade, Simponi and Stelara.

The Latest
With the pandemic bumping Euro 2020 to 2021 and the funkiness of Qatar 2022 shifting the World Cup to December, Vegas shops will welcome the sport’s return to normalcy.
During his rehab, Mueller became a father for the first time.
Advocates pushing President Biden to make this drastic, legally questionable move should stick with more reasonable measures to help a smaller number of undocumented immigrants, including DACA recipients.
He’s a great guy who says he texts his former girlfriend because he cares about other people.
This year’s draft class had the potential to be a total bust because several stars, including Clark, could have opted to return to college for a fifth season. Clark declared for the Draft in February, and a number of her peers followed, helping make this one of the deepest draft classes, and arguably most consequential in league history.